<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617536</url>
  </required_header>
  <id_info>
    <org_study_id>CR845 210301</org_study_id>
    <nct_id>NCT03617536</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
      safety and efficacy of 3 dose levels of oral CR845 compared to placebo in reducing the
      intensity of itch in chronic kidney disease (CKD) patients with moderate-to-severe pruritus.
      This study will consist of a Screening Period, a 7-day Run-in Period, a 12 week Treatment
      Period, and a Follow-up Visit (approximately 7 days after the last dose of study drug).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of a Screening Period, a 7-day Run-in Period, a 12 week Treatment
      Period, and a Follow-up Visit (approximately 7 to 10 days after the last dose of study drug).
      Informed consent will be obtained prior to performing any study-specific procedures.
      Screening will occur within 7 to 28 days prior to randomization to assess eligibility.

      If patients continue to meet all inclusion and no exclusion criteria at the end of the 7-day
      Run-in Period, they will be randomized in a 1:1:1:1 ratio to receive orally once daily either
      placebo or CR845 tablets at doses of 0.25, 0.5 or 1 mg. Randomization will be stratified
      according to the patient's renal disease status: moderate CKD; severe CKD non-dialysis;
      severe CKD on dialysis (ie, 3 categories). A final safety Follow-up Visit will be conducted 7
      to 10 days after the last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Actual">November 14, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>CR845 will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose.
CR845 tablets will be provided at doses of 0.25, 0.5, and 1 mg.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of itch-intensity as assessed by the change from baseline in weekly mean of the daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) score during Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where &quot;0&quot; represents &quot;no itching&quot; and &quot;10&quot; represents &quot;worst itching imaginable&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in itch-related quality of life as assessed by the change from baseline in total Skindex-10 Scale score at the end of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Skindex-10 Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past week. The questions cover 3 domains: disease, mood/emotional distress, and social functioning domain. A lower total score represents better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in itch-related quality of life as assessed by the change from baseline in 5-D Itch Scale score at the end of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The 5-D Itch Scale is a multidimensional questionnaire which assesses itch-related quality of life over the past 2 weeks. The questions cover five dimensions of itch including the degree, duration of itch/day, direction (improvement/worsening), disability (impact on activities such as work), and body distribution of itch. A lower total score represents better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of itch intensity as assessed by the proportion of patients achieving an improvement from baseline ≥3 points with respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Intensity of itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where &quot;0&quot; represents &quot;no itching&quot; and &quot;10&quot; represents &quot;worst itching imaginable&quot;.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>CR845 0.25 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CR845 0.25 mg to be taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR845 0.5 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CR845 0.5 mg to be taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CR845 1 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral CR845 1 mg to be taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo to be taken orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 0.25 mg Oral Tablet</intervention_name>
    <description>CR845 0.25 mg medication taken orally 1 time/day</description>
    <arm_group_label>CR845 0.25 mg Oral Tablet</arm_group_label>
    <other_name>Difelikefalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 0.5 mg Oral Tablet</intervention_name>
    <description>CR845 0.5 mg medication taken orally 1 time/day</description>
    <arm_group_label>CR845 0.5 mg Oral Tablet</arm_group_label>
    <other_name>Difelikefalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 1 mg Oral Tablet</intervention_name>
    <description>CR845 1 mg medication taken orally 1 time/day</description>
    <arm_group_label>CR845 1 mg Oral Tablet</arm_group_label>
    <other_name>Difelikefalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablet taken orally 1 time/day</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for inclusion into the study, a patient must meet the following criteria:

          -  CKD patients with stage III, IV, or V (ie, moderate renal impairment with estimated
             glomerular filtration rate (GFR) ≥30 and &lt;60 mL/min/1.73 m2 or severe renal impairment
             with estimated GFR &lt;30 mL/min/1.73 m2).

          -  For severe CKD patients on hemodialysis, they must be receiving hemodialysis 3 times
             per week for at least 3 months prior to the start of screening;

          -  Prior to randomization:

               1. Has completed at least 4 Worst Itching Intensity NRS worksheets from the start of
                  the 7-day Run-in Period;

               2. Has a mean baseline Worst Itching Intensity NRS score ≥5, defined as the average
                  of all non-missing scores reported from the start of the 7-day Run-in Period.

        Exclusion Criteria:

        A patient will be excluded from the study if any of the following criteria are met:

          -  Patients not currently on dialysis who are likely to initiate routine dialysis during
             study participation;

          -  Scheduled to receive a kidney transplant during the study;

          -  New or change of treatment received for itch including antihistamines and
             corticosteroids (oral, intravenous [IV], or topical) within 14 days prior to
             screening;

          -  Received another investigational drug within 30 days prior to the start of screening
             or is planning to participate in another clinical study while enrolled in this study;

          -  Received ultraviolet B treatment within 30 days prior to the start of screening or
             anticipates receiving such treatment during the study;

          -  Participated in a previous clinical study with CR845.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique Menzaghi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cara Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Prescott</city>
        <state>Arizona</state>
        <zip>86401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site 2</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>99309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Canyon Country</city>
        <state>California</state>
        <zip>91351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site 1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site 2</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Temple Terrace</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Zachary</city>
        <state>Louisiana</state>
        <zip>70791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site 2</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Saint Clair</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Gonzales</city>
        <state>Texas</state>
        <zip>78629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>difelikefalin</keyword>
  <keyword>CR845</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>uremic pruritus</keyword>
  <keyword>CKD</keyword>
  <keyword>CKD-aP</keyword>
  <keyword>CKD-associated pruritus</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Kidney dysfunction</keyword>
  <keyword>Generalized pruritus</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Dialysis</keyword>
  <keyword>ESRD (end stage renal disease)</keyword>
  <keyword>Kidney failure, chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

